Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In vitro immunization for the production of human monoclonal antibody

In vitro immunization for the production of human monoclonal antibody Review Keiji Koda* and Mark C. Glassy Brunswick Biotechnetics, San Diego, California, USA Introduction The usefulness of monoclonal antibodies (MAbs) in diagnostic and therapeutic applications has been intensively studied during the past decade. The majority of these clinical studies have been with murine MAbs. The lack of efficacy in most of these applications has been attributed to the innate "foreignness" of the mouse protein, which has often caused several kinds of adverse reactions in the host, such as allergic response, hepatic disfunctions, and immune complex formation in the kidney. In addition, the human antimouse antibody (HAMA) response has limited the usefulness of murine MAbs in over half the patients treated so far. 1-3 One possible solution in avoiding the HAMA and other reactions inherent with murine MAbs is the development of human MAbs. Over a decade has passed since the first report of human monoclonal antibody production using immortalization by Epstein-Barr virus (EBV) in 1977. 4 In the interim, several techniques and methodologies have been developed to generate human MAbs of clinical interest, including the production of chimeric MAbs, which substitute the constant region of mouse antibodies with human counterparts. 5 -9 However, thus far, no single approach http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

In vitro immunization for the production of human monoclonal antibody

Koda, Keiji; Glassy, Mark C.
Human Antibodies , Volume 1 (1) – Jan 1, 1990
Download PDF
8 pages

Loading next page...
 
/lp/ios-press/in-vitro-immunization-for-the-production-of-human-monoclonal-antibody-IVPq0Z9R6K

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 1990 by IOS Press, Inc
ISSN
1093-2607
eISSN
1875-869X
DOI
10.3233/HAB-1990-1104
Publisher site
See Article on Publisher Site

Abstract

Review Keiji Koda* and Mark C. Glassy Brunswick Biotechnetics, San Diego, California, USA Introduction The usefulness of monoclonal antibodies (MAbs) in diagnostic and therapeutic applications has been intensively studied during the past decade. The majority of these clinical studies have been with murine MAbs. The lack of efficacy in most of these applications has been attributed to the innate "foreignness" of the mouse protein, which has often caused several kinds of adverse reactions in the host, such as allergic response, hepatic disfunctions, and immune complex formation in the kidney. In addition, the human antimouse antibody (HAMA) response has limited the usefulness of murine MAbs in over half the patients treated so far. 1-3 One possible solution in avoiding the HAMA and other reactions inherent with murine MAbs is the development of human MAbs. Over a decade has passed since the first report of human monoclonal antibody production using immortalization by Epstein-Barr virus (EBV) in 1977. 4 In the interim, several techniques and methodologies have been developed to generate human MAbs of clinical interest, including the production of chimeric MAbs, which substitute the constant region of mouse antibodies with human counterparts. 5 -9 However, thus far, no single approach

Journal

Human Antibodies – IOS Press

Published: Jan 1, 1990

There are no references for this article.